Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Servier
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Deciphera Pharmaceuticals, LLC
Novartis
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Celgene
Emory University
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Novartis
Chang Gung Memorial Hospital
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
TransMolecular
Thallion Pharmaceuticals